The article presents a strategic vision for cancer immunotherapy developed by the Society for Immunotherapy of Cancer (SITC). Over the past 10–15 years, cancer immunotherapy has transformed oncology, with immune checkpoint inhibitors, CAR-T cell therapies, and other novel agents becoming standard of care. However, the field is now at a critical inflection point, with potential for exponential growth over the next decade. SITC convened a diverse group of experts to identify current opportunities and challenges, prioritizing areas with the highest clinical impact. The consensus group identified seven high-priority areas: mechanisms of antitumor activity and toxicity, mechanisms of drug resistance, biomarkers and biospecimens, unique aspects of novel therapeutics, host and environmental interactions, premalignant immunity, immune interception, and immunoprevention, and clinical trial design, endpoints, and conduct. Potential roadblocks to progress were also discussed, with several topics identified as cross-cutting tools for optimization, including preclinical models, data curation and sharing, biospecimens, funding diversification, definitions and standards, and patient engagement. Three key guiding principles were identified: engaging the patient community, cultivating diversity, equity, inclusion, and accessibility, and leveraging artificial intelligence to accelerate progress. The article also highlights the need for improved preclinical models, longitudinal biospecimens, and standardized definitions to better understand immunotherapy mechanisms and resistance. Additionally, the importance of patient engagement, predictive biomarkers, and innovative clinical trial designs are emphasized to improve outcomes and expand the reach of immunotherapy. The field faces challenges such as limited funding, data sharing, and the need for more effective predictive biomarkers. The article concludes with a call to action for the scientific community to prioritize these areas and collaborate to advance cancer immunotherapy.The article presents a strategic vision for cancer immunotherapy developed by the Society for Immunotherapy of Cancer (SITC). Over the past 10–15 years, cancer immunotherapy has transformed oncology, with immune checkpoint inhibitors, CAR-T cell therapies, and other novel agents becoming standard of care. However, the field is now at a critical inflection point, with potential for exponential growth over the next decade. SITC convened a diverse group of experts to identify current opportunities and challenges, prioritizing areas with the highest clinical impact. The consensus group identified seven high-priority areas: mechanisms of antitumor activity and toxicity, mechanisms of drug resistance, biomarkers and biospecimens, unique aspects of novel therapeutics, host and environmental interactions, premalignant immunity, immune interception, and immunoprevention, and clinical trial design, endpoints, and conduct. Potential roadblocks to progress were also discussed, with several topics identified as cross-cutting tools for optimization, including preclinical models, data curation and sharing, biospecimens, funding diversification, definitions and standards, and patient engagement. Three key guiding principles were identified: engaging the patient community, cultivating diversity, equity, inclusion, and accessibility, and leveraging artificial intelligence to accelerate progress. The article also highlights the need for improved preclinical models, longitudinal biospecimens, and standardized definitions to better understand immunotherapy mechanisms and resistance. Additionally, the importance of patient engagement, predictive biomarkers, and innovative clinical trial designs are emphasized to improve outcomes and expand the reach of immunotherapy. The field faces challenges such as limited funding, data sharing, and the need for more effective predictive biomarkers. The article concludes with a call to action for the scientific community to prioritize these areas and collaborate to advance cancer immunotherapy.